JKS enters the week of September 15 with every signal pointing the same direction: a stock in distress, with short sellers rebuilding positions into a 36% monthly collapse and options traders betting more on calls than puts — an unusual divergence that tells two very different stories about where investors think this goes next.
The price action alone is striking. JKS closed at $10.71 on Tuesday, down 5.6% on the day and 13.8% for the week. The month-long drop of 36% has left the stock trading at just 0.24x book value — a level that screams distress rather than value. Following the most recent earnings print on August 26, the stock fell 12.8% the next day and shed nearly 20% over the following five sessions. That reaction sets a difficult baseline heading into the next report, due October 30.
Short positioning tells a clear story of growing conviction on the bear side. Short interest climbed nearly 18% over the past week to 7.1% of the free float — a meaningful level, and rising. The jump came almost entirely from a single-day surge around September 9, when shorts added roughly 600,000 shares in one session. Despite that build, the borrow market remains surprisingly easy. Availability runs at 129%, meaning shares to borrow comfortably exceed shares already shorted. Cost to borrow is just 0.60% — barely above the general collateral rate — confirming there is no friction in the lending pool. Shorts can add freely without a squeeze threat materialising from the mechanics of the borrow market. The ORTEX short score has edged up to 70.1, its highest reading in the ten-day window tracked here, ranking JKS in the bottom 4th percentile of its universe on short score rank — a persistently bearish signal.
Options positioning cuts against the short story, and that contrast is worth naming. The put/call ratio is running at 0.40, well below its 20-day average of 0.45 and near its 52-week low of 0.40 set just the day before. That's almost one standard deviation below the mean — not the profile of a market bracing for further downside. Instead, it points to call-heavy positioning: traders buying upside rather than protection. Whether that reflects genuine recovery bets or short-seller hedging is unclear, but the setup is unusual for a stock falling this aggressively. The 52-week PCR high of 1.72 shows the market has seen far more defensive positioning at points this year.
The Street has little enthusiasm, though the most recent analyst action warrants attention. Roth Capital's Philip Shen cut his target on JKS from $25 to $16 at the end of August — a 36% reduction — while keeping a Neutral rating. With the stock now at $10.71, even that revised target implies material upside, though the direction of travel on targets has been uniformly downward. Goldman Sachs has maintained a Sell rating throughout, most recently with a $20 target set in November 2025. The consensus mean price target of $22.73 implies more than 100% upside from current levels, but the gap between the target and the price reflects how far the stock has fallen since those estimates were set rather than genuine analyst optimism. EPS momentum over both 30 and 90 days ranks in the bottom 3rd and 4th percentile of the universe — the earnings revision trend is pointing sharply lower.
Insider activity adds a further cautionary note. Over the 90 days through July 1, insiders were net sellers of approximately 1.3 million shares, realising around $33.5 million. Director LI XIANHUA sold 1.28 million shares at $25.53 in May — a transaction worth $32.7 million — executed while the stock traded well above current levels. Those sales now look prescient. Xianhua Li subsequently trimmed her institutional holding by 127,000 shares as well. Meanwhile, BlackRock added 536,000 shares as of August 31 and Storebrand, Invesco, and UBS Asset Management all added meaningfully in the most recent reporting period — a quiet institutional accumulation that at least partially offsets the insider selling narrative.
What to watch next: the October 30 earnings event is the clearest near-term focus, given that the August print produced a 12.8% one-day drawdown and a 20% five-day move, and the stock is now trading at a fraction of where it was when those results landed.
See the live data behind this article on ORTEX.
Open JKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
